Cumberland Pharmaceuticals (CPIX) Share-based Compensation (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Share-based Compensation of $106842.0 for Q1 2026, up 43.97% on a YoY basis from $74212.0 in Q1 2025, and down 47.15% sequentially from $202151.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Share-based Compensation (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Share-based Compensation data on file, last reported at $106842.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 43.97% year-over-year to $106842.0; the trailing twelve-month figure through Mar 2026 stood at $470941.0 (up 281.34% YoY), and the FY2025 full-year result was $438311.0, up 242.33% from the prior year.
- Share-based Compensation slipped to $106842.0 in Q1 2026, from $202151.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.3 million in Q4 2022 to a low of -$99044.0 in Q4 2024.
- A 5-year average of $377796.3 and a median of $83112.0 in 2023 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 925.86% in 2022, while the deepest fall reached 114.46% in 2022.
- Tracing CPIX's Share-based Compensation over 5 years: stood at $4.3 million in 2022, then tumbled by 79.22% to $887221.0 in 2023, then sank by 111.16% to -$99044.0 in 2024, then jumped by 304.1% to $202151.0 in 2025, then slumped by 47.15% to $106842.0 in 2026.
- Business Quant data shows CPIX's Share-based Compensation at $106842.0 in Q1 2026, $202151.0 in Q4 2025, and $81262.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Cumberland Pharmaceuticals | 104.57 Mn | 93.23 Mn | 7.20 Mn | 106,842.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106,842.00 |
| Mar 31, 2026 | 106,842.00 |
| Dec 31, 2025 | 202,151.00 |
| Dec 31, 2025 | 202,151.00 |
| Sep 30, 2025 | 81,262.00 |
| Sep 30, 2025 | 81,262.00 |
| Jun 30, 2025 | 80,686.00 |
| Jun 30, 2025 | 80,686.00 |
| Mar 31, 2025 | 74,212.00 |
| Mar 31, 2025 | 74,212.00 |
| Dec 31, 2024 | -99,044.00 |
| Dec 31, 2024 | -99,044.00 |
| Sep 30, 2024 | 76,371.00 |
| Sep 30, 2024 | 76,371.00 |
| Jun 30, 2024 | 71,958.00 |
| Jun 30, 2024 | 71,958.00 |
| Mar 31, 2024 | 78,754.00 |
| Mar 31, 2024 | 78,754.00 |
| Dec 31, 2023 | 887,221.00 |
| Dec 31, 2023 | 887,221.00 |